UNSPSC 51142555: Mazaticol hydrochloride

This classification denotes an anticholinergic agent with the molecular formula C20H25NO3S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 44WQI5180Q, chemically known as 6,6,9-trimethyl-9-azabicyclo(3.3.1)non-3beta-yl-alpha,alpha-di-(2-thienyl)glycolate hydrochloride but more generally known as mazaticol hydrochloride, which bears US NIH Compound Identifier 135004. European Medicines Agency schedules Mazaticol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03096MIG.

Most nations, for tariff and trade purposes, schedule mazaticol hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, MAZATICOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC1(CCC2CC(CC1N2C)OC(=O)C(C3CCCS3)(C4CCCS4)O)C.CL.

UNSPSC 51142555 Mazaticol hydrochloride is a Commodity code that in current state and local procurement activity covers naloxone, drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products supplied through authorized distribution channels to public health agencies and state benefit programs. The issuing bodies soliciting under this code include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances that coordinate procurement on behalf of participating state and local government entities. The scope of work encompasses emergency response medications and harm-reduction supplies for community health initiatives, direct-to-manufacturer pharmaceutical programs designed to optimize prescription fulfillment and cost management, and bulk generic pharmaceutical and OTC product procurement through established wholesaler networks with compliance requirements including Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, and FDA approval.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2026, and quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission issued Request for Information HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program targeting direct contracting between the state and pharmaceutical manufacturers outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released Request for Proposal S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026, response deadline and July 1, 2026, contract effective date; vendors must maintain relationships with authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and the RFP weights price competitiveness at 75 percent of evaluation criteria.